Vasovasostomy is a microsurgical procedure to restore fertility after vasectomy, a surgery that sterilizes the patient by severing the vas deferentia, the tubes that carry the sperm from the testes to the penis. After a vasectomy, a patient may have various reasons for wanting to reverse the procedure, such as new opportunities for having children or a new romantic partnership. A vasovasostomy involves reestablishing the flow of sperm through the vas deferens by reconnecting the severed ends of the tube. In 1919, in the United States, William C. Quinby performed the first recorded successful vasovasostomy. Modern improvements on the surgery have led to its adoption as a microsurgery, a procedure that involves a microscope and specialized microscopic instruments. Surgical research over the twentieth century into reconnecting a blocked vas deferens and the resulting microsurgical technique for vasovasostomy has provided a way for people to regain their fertility after a vasectomy.

Phalloplasty is a type of surgery that takes existing skin, tissue, and nerves from surrounding areas on a patient’s body to repair or form a neophallus, or a new penis structure. In 1946, Harold Gillies, a plastic surgeon who practiced in England, performed one of the first modern phalloplasties that entailed creating an entire neophallus for a transsexual, called transgender as of 2022, man in London, England. The reconstructive need for phalloplasties started as a result of treating blast wounds during World War I and World War II. The techniques from that time allowed Gillies to perform a phalloplasty with urethral lengthening. Lengthening the urethra allows the patient to use the neophallus to urinate, for a transgender person as a means of affirming their gender identity. Phalloplasty procedures improve the quality of life for people who have congenital conditions, physical trauma, or are seeking gender affirmation surgery.

No-scalpel vasectomy, or NSV or keyhole vasectomy, is a surgical method of sterilization that involves puncturing the skin of the scrotum to access the vas deferens, a tube that carries spermatozoa, or sperm, from the testes to the penis. The surgeon performing the procedure blocks the flow of sperm through the vas deferens, sterilizing the patient. NSV is a less invasive procedure, as it does not use a scalpel to make a deep cut on sensitive scrotal tissue. Typically, urologists perform NSV with the purpose of rendering the patient sterile while not altering other functions of the testes, scrotum, and penis. Li Shunqiang developed the technique in China in 1974 as a less invasive method of vasectomy for male patients. Li’s development of NSV provided an alternative method to vasectomies that rely on making incisions into the scrotum with a blade. NSV gained wide use as a sterilization technique, providing a path for males to take greater responsibility for contraception and family planning.

The NuvaRing is a self-administered hormonal contraceptive device in the form of a flexible plastic ring that is inserted into the vagina. It releases the hormones etonogestrel and ethinylestradiol, which are synthetic forms of the female reproductive hormones progesterone and estrogen, respectively. The pharmaceutical company Organon first made NuvaRing in the Netherlands in 1980s. The Netherlands first approved it for use in February of 2001, and the United States did the same in October of that year. To insert the NuvaRing, a user pinches the ring together to compress it and inserts it into the vaginal canal, where its exact placement does not matter. The NuvaRing stays in the vagina for three weeks, after which the user removes it for one week. During the week following removal, the user experiences bleeding similar to a menstrual period. The NuvaRing was one of the first monthly vaginal rings used for contraception, and it provides a self-administered method of birth control, which can be more accessible for some users than taking a birth control pill every day.

Gender-affirming mastectomy is a type of surgery that removes breast tissue, tightens the skin, and can adjust nipple placement to provide the desired results of a more masculine-looking chest. Mastectomies started as a way for surgeons to remove breast cancer and tumors from the breast tissue. However, as of 2022, surgeons also use the procedure as a means of gender-affirming surgery for transgender and non-binary, hereafter TNB, individuals. If a person identifies as transgender, their gender identity differs from the sex they were assigned at birth and the gender they were most likely raised as, which can produce gender dysphoria, a condition that can last a lifetime. Non-binary individuals may have a similar experience, but they identify outside of or between the identifiers of man and woman. Gender-affirming mastectomy, sometimes called top surgery, improves the quality of life for people who seek the appearance of a masculine chest to both better integrate themselves into society and lessen the mental and emotional burden of gender dysphoria.

In October 2013, Jürgen Dinger, Sabine Möhner, and Klaas Heinemann published the article “Cardiovascular Risk Associated With the Use of an Etonogestrel-Containing Vaginal Ring,” hereafter “Cardiovascular Risk,” in the journal Obstetrics and Gynecology. The authors enrolled patients in the study who were new users of either a vaginal contraceptive ring known as NuvaRing or a combined oral contraceptive pill. A combined oral contraceptive pill contains a formulation of the hormones progesterone and estrogen. They followed up with the patients for two to four years after they had started either hormonal contraceptive treatment to record the incidence of specific cardiovascular events. The authors found that the risks of cardiovascular events when starting use of either NuvaRing or a combined hormonal contraceptive pill were similar to each other in the patients they studied. The results of “Cardiovascular Risk” affirmed the results of similar studies and stated that the risk of cardiovascular events was similar in NuvaRing users to other contraceptive users.